Ardsley Advisory Partners LP Purchases 100,000 Shares of Indivior PLC $INDV

Ardsley Advisory Partners LP grew its holdings in shares of Indivior PLC (NASDAQ:INDV) by 16.0% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 725,000 shares of the company’s stock after purchasing an additional 100,000 shares during the quarter. Indivior makes up approximately 1.4% of Ardsley Advisory Partners LP’s holdings, making the stock its 17th biggest position. Ardsley Advisory Partners LP owned about 0.53% of Indivior worth $10,686,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Indivior by 16.0% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,820 shares of the company’s stock worth $71,000 after purchasing an additional 666 shares in the last quarter. Y Intercept Hong Kong Ltd increased its position in Indivior by 17.4% in the second quarter. Y Intercept Hong Kong Ltd now owns 25,443 shares of the company’s stock worth $375,000 after buying an additional 3,769 shares in the last quarter. Amalgamated Bank bought a new position in shares of Indivior in the second quarter worth about $61,000. CTC Alternative Strategies Ltd. bought a new position in shares of Indivior in the first quarter worth about $96,000. Finally, Prudential Financial Inc. purchased a new position in shares of Indivior during the 2nd quarter valued at about $207,000. Hedge funds and other institutional investors own 60.33% of the company’s stock.

Indivior Stock Performance

Shares of Indivior stock opened at $36.01 on Wednesday. Indivior PLC has a twelve month low of $7.62 and a twelve month high of $38.00. The business has a 50-day moving average price of $29.04 and a 200-day moving average price of $22.40.

Indivior (NASDAQ:INDV) last announced its quarterly earnings results on Thursday, October 30th. The company reported $0.72 EPS for the quarter, beating analysts’ consensus estimates of $0.38 by $0.34. The company had revenue of $314.00 million during the quarter, compared to analyst estimates of $257.66 million. Indivior had a negative return on equity of 90.79% and a net margin of 9.83%. Sell-side analysts expect that Indivior PLC will post 1.22 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the stock. Piper Sandler reissued an “overweight” rating and issued a $41.00 target price (up from $27.00) on shares of Indivior in a report on Friday, October 31st. Weiss Ratings reissued a “hold (c)” rating on shares of Indivior in a research note on Friday, October 31st. HC Wainwright lifted their target price on shares of Indivior from $28.00 to $35.00 and gave the company a “buy” rating in a research note on Thursday, October 30th. Northland Securities set a $40.00 target price on shares of Indivior in a report on Friday, October 31st. Finally, Zacks Research raised Indivior from a “hold” rating to a “strong-buy” rating in a report on Monday, November 3rd. Two research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $32.71.

Indivior Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.